Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152K | $152K | $152K | $152K | $152K | $6.69M | $2.79M | $234M | $329M | $616M |
| Revenue growth | — | 0.0% | 0.0% | 0.0% | 0.0% | 4300.7% | -58.4% | 8290.0% | 40.8% | 87.3% |
| Operating income | -$79.0M | -$119M | -$174M | -$169M | -$274M | -$345M | -$218M | $20.6M | $41.9M | $123M |
| Operating margin | -51953.3% | -78100.0% | -114736.8% | -111220.4% | -179996.1% | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Net income | -$78.3M | -$118M | -$173M | -$173M | -$279M | -$348M | -$224M | $12.7M | $23.4M | $447M |
| Net margin | -51482.2% | -77944.7% | -114132.9% | -113730.9% | -183803.3% | -5204.1% | -8036.3% | 5.4% | 7.1% | 72.6% |
| EPS (diluted) | -$1.60 | -$1.91 | -$2.30 | -$1.96 | -$2.42 | -$2.63 | -$1.65 | $0.09 | $0.15 | $2.77 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$61.6M | -$93.8M | -$129M | -$133M | -$215M | -$296M | -$176M | -$31.4M | -$40.5M | -$24.8M |
| Capital expenditures | $344K | $2.00K | $90.0K | $131K | $357K | $401K | $14.0K | $0.00 | $45.0K | $214K |
| Free cash flow | -$61.9M | -$93.8M | -$129M | -$133M | -$215M | -$296M | -$176M | -$31.4M | -$40.6M | -$25.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25.0M | $56.7M | $42.0M | $113M | $553M | $299M | $102M | $92.9M | $180M | $79.1M |
| Total assets | $54.8M | $97.4M | $83.6M | $163M | $626M | $380M | $194M | $330M | $578M | $1.06B |
| Total liabilities | $18.9M | $30.4M | $59.6M | $124M | $106M | $142M | $135M | $169M | $355M | $415M |
| Long-term debt | — | — | $0.00 | $29.0M | $7.72M | $66.8M | $71.1M | $100M | $244M | $246M |
| Shareholders' equity | $35.9M | $67.0M | $24.0M | $38.6M | $519M | $237M | $58.6M | $161M | $222M | $648M |
| Retained earnings | -$236M | -$355M | -$528M | -$701M | -$981M | -$1.33B | -$1.53B | -$1.55B | -$1.53B | -$1.08B |
| Shares (wtd avg diluted) | 56.8M | 73.1M | 83.9M | 109M | 115M | 132M | 135M | 149M | 160M | 161M |
Every figure is extracted from TG THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.